ClinicalTrials.gg
WithdrawnNCT03389061CRUSADE-1Updated Dec 7, 2020

Bioequivalence Study of Crushed Sofosbuvir/Velpatasvir Compared to the Whole Tablet

A Phase 4 interventional study of sofosbuvir/velpatasvir tablet and sofosbuvir/velpatasvir crushed in HCV, sponsored by Radboud University Medical Center. Withdrawn at 3 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-12-07.

Sponsored by Radboud University Medical Center · Phase 4, Interventional, and Other

Why this study was withdrawn
Lack of patients who are eligible for inclusion: less patients on treatment and not using epclusa.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Epclusa® is a pan-genotypic, once-daily tablet for the treatment of chronic hepatitis C virus (HCV) infection containing the NS5B- polymerase inhibitor sofosbuvir (SOF, nucleotide analogue) 400 mg and the NS5A inhibitor velpatasvir (VEL) 100 mg.

For patients with swallowing difficulties, administration of whole tablets can be problematic. In addition, HCV patients that are hospitalized (at intensive care units) due to severe illness (co-infections/ liver failure) might not be able to swallow medication. Therefore it is useful to know whether it is possible to administer SOF/VEL through a different route, like a feeding tube.

In daily practice, information about the safety and efficacy of crushed tablets is lacking which might result in interruption or discontinuation of expensive HCV therapy. However, it is not recommended to interrupt treatment because there is no evidence about the efficacy of the therapy after discontinuation (and restart).

Currently, patients and healthcare professionals are crushing SOF/VEL tablets without information about efficacy and safety. Depending on the biopharmaceutical characteristics of a drug formulation, crushing tablets can lead to altered pharmacokinetics of drugs.

It is important to know whether pharmacokinetic parameters are influenced by crushing of tablets; both a decrease and an increase in exposure may occur. A decrease of the plasma concentrations of SOF and/or VEL potentially reduces the therapeutic effect of the drugs. Higher doses or switching to other HCV-drugs might be needed. In contrast, in case a higher Cmax,ss and/or exposure occurs there might be an increased risk of toxicity.

As a result, crushing the drug is a contra-indication based on the available data.

Therefore this study will be conducted to investigate whether a crushed SOF/VEL tablet is bioequivalent to SOF/VEL as a whole tablet.

02

Conditions studied

  • HCV

Browse trials for

Keywords

  • Epclusa
  • Pharmacokinetics
  • Crushing
03

In context

Pressure Ulcer

546 studies on the registry are indexed under Pressure Ulcer; 126 are open to participants now.

Browse Pressure Ulcer studies →

Lead sponsor

Radboud University Medical Center is the lead sponsor of 986 studies on the registry; 135 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with SOF/VEL treatment for the treatment of chronic genotype 1 through 6.
  2. Patient is at least 18 at the day of screening.
  3. Patient is able and willing to sign the Form.
  4. Patient is able and willing to follow protocol requirements.

Exclusion criteria

Exclusion Criteria:

  1. Pregnant female (as confirmed by an hCG urine test performed at screening) or breast-feeding female.
  2. Relevant history or current condition that might interfere with drug absorption, distribution, metabolism or excretion.
  3. Inability to understand the nature and extent of the study and the procedures required.
  4. low concentration at screening judged by the patient's own hepatologist.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 4
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Active comparator
    sofosbuvir/velpatasvir tablet

    Single-dose sofosbuvir/velpatasvir as a whole tablet in a fasted state.

    Drug: sofosbuvir/velpatasvir tablet

  • Experimental
    sofosbuvir/velpatasvir crushed

    Single-dose crushed sofosbuvir/velpatasvir in a fasted state.

    Drug: sofosbuvir/velpatasvir crushed

Interventions

  • Drugsofosbuvir/velpatasvir tablet

    Drug pages: Sofosbuvir · Velpatasvir

    Single-dose SOF/VEL as a whole tablet in a fasted state.

  • Drugsofosbuvir/velpatasvir crushed

    Single-dose crushed SOF/VEL in a fasted state.

06

What researchers measure

Primary outcomes

  1. AUC

    Time frame: Up to 24 hours after administration

  2. Cmax

    Time frame: one dosing interval after administration of SOF/VEL (up to 24 hours)

Secondary outcomes

  1. Adverse events

    Time frame: During the entire conduct of the study, maximum of two weeks

07

Study locations

3 sites
  • University of Bonn, Germany
    Bonn, Germany
  • Jeroen Bosch Hospital
    's-Hertogenbosch, Netherlands
  • Radboud university medical center Department of GI tract
    Nijmegen, Netherlands
08

References and documents

Publications

  • van Seyen M, Samson AD, Cullen L, Eastick K, Knol H, Colbers A, Burger DM. Crushed application of sofosbuvir and velpatasvir in a patient with swallowing disorder. Int J Antimicrob Agents. 2020 Jun;55(6):105934. doi: 10.1016/j.ijantimicag.2020.105934. Epub 2020 Mar 7. No abstract available. PubMed 32156618 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2018 to primary completion in Mar 2019, 11 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2017
First posted
Jan 3, 2018
StartActual
Apr 1, 2018
Primary completionActual
Mar 22, 2019
CompletionActual
Mar 22, 2019
Last update
Dec 7, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 7, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03389061
Responsible party
Sponsor
First posted
Jan 3, 2018
Start date
Apr 1, 2018
Primary completion
Mar 22, 2019
Completion
Mar 22, 2019
Last update
Dec 7, 2020

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion